Literature DB >> 17012295

Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway.

Colin L Masters1, Konrad Beyreuther.   

Abstract

It is now 100 years since the nosological definition of Alzheimer's disease emerged. In the first 80 years, very little progress was made in understanding the mechanisms that caused the brain to degenerate in a remarkably specific fashion (amyloid accumulation with neurofibrillary changes). Over the past 20 years, there has been an explosion of knowledge which continues today at an exponential rate. The molecular pathways underlying the synaptic dysfunction in Alzheimer's disease have delivered many validated therapeutic and diagnostic targets. A variety of therapeutic strategies aimed at disease modification are now in clinical development.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17012295     DOI： 10.1093/brain/awl251

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


  46 in total

1.  Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.

Authors:  Hailin Zheng; Moussa B H Youdim; Mati Fridkin
Journal:  ACS Chem Neurosci       Date:  2010-10-04       Impact factor: 4.418

2.  Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion.

Authors:  Irfan Y Tamboli; Esther Barth; Leonie Christian; Martin Siepmann; Sathish Kumar; Sandesh Singh; Karen Tolksdorf; Michael T Heneka; Dieter Lütjohann; Patrick Wunderlich; Jochen Walter
Journal:  J Biol Chem       Date:  2010-09-28       Impact factor: 5.157

Review 3.  Alzheimer's disease and mild cognitive impairment.

Authors:  Brendan J Kelley; Ronald C Petersen
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

4.  Transient reduction of spontaneous neuronal network activity by sublethal amyloid beta (1-42) peptide concentrations.

Authors:  Philipp Görtz; Jessica Opatz; Mario Siebler; Susanne Aileen Funke; Dieter Willbold; Christian Lange-Asschenfeldt
Journal:  J Neural Transm (Vienna)       Date:  2009-02-13       Impact factor: 3.575

Review 5.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

6.  Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance.

Authors:  Mitsuru Shinohara; Naoyuki Sato; Hitomi Kurinami; Daisuke Takeuchi; Shuko Takeda; Munehisa Shimamura; Toshihide Yamashita; Yasuo Uchiyama; Hiromi Rakugi; Ryuichi Morishita
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

7.  A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer's disease.

Authors:  Shaker El-Sappagh; Jose M Alonso; S M Riazul Islam; Ahmad M Sultan; Kyung Sup Kwak
Journal:  Sci Rep       Date:  2021-01-29       Impact factor: 4.379

8.  The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation.

Authors:  Subathra Murugan; Padmaja Jakka; Swapna Namani; Varadendra Mujumdar; Girish Radhakrishnan
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

9.  Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities.

Authors:  Xiangyou Hu; Qi Shi; Xiangdong Zhou; Wanxia He; Hong Yi; Xinghua Yin; Marla Gearing; Allan Levey; Riqiang Yan
Journal:  EMBO J       Date:  2007-05-03       Impact factor: 11.598

10.  Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment.

Authors:  Remy Robert; Victor A Streltsov; Janet Newman; Lesley A Pearce; Kim L Wark; Olan Dolezal
Journal:  Protein Sci       Date:  2010-02       Impact factor: 6.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.